Jeffrey Jones MD, MPH, MBA

Dr. Jeffrey Jones has over 15 years of clinical development experience in academia and industry, with skills ranging from clinical trials, drug development, medical education, and healthcare management. Previously, Dr. Jones served as Vice President, Global Drug Development, Lymphoma and Myeloid Diseases at Bristol Myers Squibb, where he led the development and life cycle management strategy for Reblozyl®. Earlier, Dr. Jones was Clinical Strategy Lead for Lymphoma and Chronic Lymphocytic Leukemia, Global Clinical Research and Development at Celgene, where he shaped clinical and business development strategy across a diverse portfolio of small and large molecules in early- through late-stage development.

Before joining the industry in 2017, Dr. Jones was an Associate Professor of Internal Medicine in the Division of Hematology at The Ohio State University. While at Ohio State, Dr. Jones led the Chronic Lymphocytic Leukemia clinical research program and represented the Division of Hematology as Clinical Research Leader in the OSU Comprehensive Cancer Center. Dr. Jones holds an M.B.A. from The Ohio State University Fisher College of Business, an M.P.H. from the University of Texas School of Public Health, and an M.D. from the University of Michigan Medical School, completing his residency in internal medicine at McGill University.